BioCentury
ARTICLE | Clinical News

Allecra reports Phase II data for AAI101 combo to treat cUTI

March 30, 2018 3:16 PM UTC

Allecra Therapeutics GmbH (Lörrach, Germany) reported top-line data from the Phase II CACTUS trial in 45 hospitalized adults with complicated urinary tract infections (cUTIs), including pyelonephritis, showing that AAI101 in combination with cefepime was well tolerated. Patients in the double-blind trial received 500 or 750 mg IV AAI101 plus cefepime or cefepime alone given three times daily for 7-10 days.

Allecra also said that 83% (20/24) of patients who received AAI101 plus cefepime achieved complete microbiological eradication, defined as baseline qualifying bacterial pathogen reduced to <103 colony-forming units (CFUs)/mL, vs. 73% (11/15) of patients who received cefepime alone. Additionally, 97% (29/30) of patients who received AAI101 plus cefepime achieved clinical cure, defined as complete resolution of the baseline signs and symptoms of cUTI such that no further antimicrobial therapy for the infection is needed, vs. 93% (14/15) of patients who received cefepime alone...

BCIQ Company Profiles

Allecra Therapeutics GmbH